𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recommendations for the care of oral involvement in patients with systemic sclerosis

✍ Scribed by Alp Alantar; Jean Cabane; Eric Hachulla; Guy Princ; Danielle Ginisty; Michel Hassin; Marc Sorel; Louis Maman; Aurélie Pilat; Luc Mouthon

Publisher
Wiley (John Wiley & Sons)
Year
2011
Tongue
English
Weight
126 KB
Volume
63
Category
Article
ISSN
2151-464X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

D-penicillamine treatment of lung involv
D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma)
✍ Thomas A. Medsger Jr. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 2 views

D-penicillamine has been used to treat systemic sclerosis (scleroderma) for nearly two decades. Improvement in cutaneous fibrosis in patients treated with this drug has been documented in a number of uncontrolled studies (1). The effect of D-penicillamine on established visceral involvement due to s

Improvement of vascular endothelial func
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis
✍ P. P. Sfikakis; C. Papamichael; K. S. Stamatelopoulos; D. Tousoulis; K. G. Fragi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Abstract ## Objective Increased endothelin activity may play a role in the pathogenesis of vascular injury, a primary feature of systemic sclerosis (SSc; scleroderma). Our goal was to test the hypothesis that treatment with the oral endothelin receptor antagonist bosentan might improve vascular